BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38004528)

  • 1. Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients.
    Cura Y; Sánchez-Martín A; Márquez-Pete N; González-Flores E; Martínez-Martínez F; Pérez-Ramírez C; Jiménez-Morales A
    Pharmaceutics; 2023 Oct; 15(11):. PubMed ID: 38004528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of new SNPs associated with severe toxicity to capecitabine.
    Pellicer M; García-González X; García MI; Robles L; Grávalos C; García-Alfonso P; Pachón V; Longo F; Martínez V; Blanco C; Iglesias I; Sanjurjo M; López-Fernández LA
    Pharmacol Res; 2017 Jun; 120():133-137. PubMed ID: 28347776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
    Matsumoto N; Kubota Y; Ishida H; Sekido M; Ohkuma R; Ishiguro T; Hirasawa Y; Ariizumi H; Tsunoda T; Ikusue T; Kobayashi K; Hisamatsu A; Toshima H; Shimada K; Fujita KI
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1119-1128. PubMed ID: 32458030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer.
    Cura Y; Sánchez-Martín A; Márquez-Pete N; González-Flores E; Martínez-Martínez F; Pérez-Ramírez C; Jiménez-Morales A
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of pharmacogenetics in capecitabine efficacy and toxicity.
    Lam SW; Guchelaar HJ; Boven E
    Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
    Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
    Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
    de With M; van Doorn L; Maasland DC; Mulder TAM; Oomen-de Hoop E; Mostert B; Homs MYV; El Bouazzaoui S; Mathijssen RHJ; van Schaik RHN; Bins S
    Biomed Pharmacother; 2023 Mar; 159():114232. PubMed ID: 36630849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
    Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
    van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ
    Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.
    Varma A; Mathaiyan J; Shewade D; Dubashi B; Sunitha K
    J Clin Pharm Ther; 2020 Aug; 45(4):617-627. PubMed ID: 32399998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
    Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
    Deenen MJ; Tol J; Burylo AM; Doodeman VD; de Boer A; Vincent A; Guchelaar HJ; Smits PH; Beijnen JH; Punt CJ; Schellens JH; Cats A
    Clin Cancer Res; 2011 May; 17(10):3455-68. PubMed ID: 21498394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
    Punt CJA; Heinemann V; Maughan T; Cremolini C; Van Cutsem E; McDermott R; Bodoky G; André T; Osterlund P; Teske AJ; Pfeiffer P
    ESMO Open; 2023 Apr; 8(2):101199. PubMed ID: 37018874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.
    Lam SW; van der Noort V; van der Straaten T; Honkoop AH; Peters GJ; Guchelaar HJ; Boven E
    Pharmacol Res; 2018 Feb; 128():122-129. PubMed ID: 28827188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
    Scheithauer W; McKendrick J; Begbie S; Borner M; Burns WI; Burris HA; Cassidy J; Jodrell D; Koralewski P; Levine EL; Marschner N; Maroun J; Garcia-Alfonso P; Tujakowski J; Van Hazel G; Wong A; Zaluski J; Twelves C;
    Ann Oncol; 2003 Dec; 14(12):1735-43. PubMed ID: 14630678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy.
    Liu D; Li X; Li X; Zhang M; Zhang J; Hou D; Tong Z; Dong M
    Cancer Chemother Pharmacol; 2019 May; 83(5):939-949. PubMed ID: 30877365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
    Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review.
    Cura Y; Pérez-Ramírez C; Sánchez-Martín A; Membrive-Jimenez C; Valverde-Merino MI; González-Flores E; Morales AJ
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients.
    van Huis-Tanja LH; Ewing E; van der Straaten RJ; Swen JJ; Baak-Pablo RF; Punt CJ; Gelderblom AJ; Guchelaar HJ
    Pharmacogenet Genomics; 2015 Jun; 25(6):279-88. PubMed ID: 25815774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.